Companies
BioLife Solutions
supplies CryoStor and BloodStor biopreservation media and CellSeal CryoCase cold-chain packaging, the cryopreservation technology layer used across biobanking and cell/gene-therapy manufacturing.
- Country
- United States
- Ticker
- BLFS
Commercial
CryoStor / BloodStor biopreservation media
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Capacity | Strengthening manufacturing and cold-chain capacity via new 40,000-square-foot Noblesville facility | hoodline.com |
| Certification | ISO 13485:2016 and ISO 9001:2015 | filecache.investorroom.com · sec.gov |
| Regulatory approval | Maintain Type II Master Files at FDA for CryoStor, HypoThermosol, and Cell Thawing Media | biolifesolutions.com · sec.gov |
| Production site | Bothell, WA; Indianapolis, IN; Woodinville, WA; Noblesville, IN (planned) | filecache.investorroom.com · hoodline.com · filingexplorer.com · sec.gov |
| Headcount | 155 full-time employees as of Dec 31, 2025 | filingexplorer.com |
| Revenue | $96.2 million for full year 2025 | prnewswire.com · sec.gov |
Independent sources: filecache.investorroom.com · filingexplorer.com · hoodline.com · prnewswire.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biobanks of human & population samples | diagnostics-medtech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.